(TheNewswire)
-
MindBio nominated for prestigiousawards including
Company of the Year and LSDCompany of the Year
-
MindBio Co-Founder Justin Hankanominated
for two awards: Entrepreneur ofthe Year and Innovator of the Year
Vancouver, British Columbia – TheNewswire - September 22, 2022 – Blackhawk GrowthCorp. (CSE:BLR ) ; ( Frankfurt:0JJ) (the “ Company ” or “ Blackhawk ”) ispleased to report that its subsidiary, MindBio Therapeutics(“MindBio”), and its Co-Founder Justin Hanka, have been nominatedfor a number of annual awards by global industry peers in the annualMicrodose Awards.
Investors can vote for MindBio and Co-Founder JustinHanka here
MindBio has been nominated in the category of Companyof the Year alongside industry leaders Cybin, Dr. Bronner’s, Microdose Therapeutics andPsilera. MindBio is also nominated in the category for LSD Companyof the Year alongside Beckley Psytech, BetterLife Pharma, MindMed andPsygen.
MindBio’s Co-Founder Justin Hanka has been nominatedfor Entrepreneur of the Year alongside industry leaders ChristianAngermayer, David Champion, Iri Selkirk and Chris Witowski.
Mr Hanka has also been nominated in the category ofInnovator of the Year alongside industry leaders Najla Guthrie, Dr.Darryl Hudson, Lars Christian Wilde and Jacki Von Salm.
The awards will be presented at the upcoming WonderlandConvention in Miami in November.
MindBio is also pleased to announce that preparationsare well underway for the start of their Phase 2 Clinical trials andfurther announcements will be made after the presentation and revealof data from their Phase 1 LSD Microdosing Clinical Trials in 80healthy subjects.
“MindBio is leading the way in psychedelicmicrodosing clinical trials. With the recent successful completionof MindBio’s Phase 1 clinical trial, the MindBio team is nowpreparing for Phase 2 Clinical Trials and progressing its work with astrong focus towards commercialization,” said Frederick Pels, CEO ofBlackhawk.
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States.
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.